A new blog post coauthored by Schaeffer Center experts in Health Affairs finds that insurer preferences for biologic and biosimilar drugs adds cost and complicates the work of hospital pharmacists and physicians.
Schaeffer Center expert Mireille Jacobson co-authored an op-ed in STAT examining why hospitals and health systems are not investing in palliative care despite research showing this type of therapy substantially improves outcomes for patients with serious illness.
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.
The lesson from past campaigns is that even good and safe vaccines need boosters, and not just the kind with needles. Psychology and behavioral science provide some key insights about how a public service campaign should be designed.
Rising immunity from vaccines and prior exposure means we should have COVID-19 cornered by Memorial Day. That doesn’t mean the virus will be out of our lives. But its impact should be reduced to something approaching a normal flu season in terms of deaths and hospitalizations.
A look at how policymakers can reform an interim-final rule to use Medicare’s demonstration authority under the Center for Medicare and Medicaid Innovation (CMMI) to make large reductions in the amounts it pays physicians for high-cost medicines they administer under Part B.
The most ethically justified path forward for COVID-19 vaccine distribution is to focus on individuals 65 and older. This group accounts for 80% of COVID-19 deaths despite making up only 16% of the population.